An interesting article on the use of « time to benefit » as an endpoint in trials of cholesterol-lowering drugs.

https://www.lipidjournal.com/article/S1933-2874(18)30204-6/fulltext

Apabetalone is not a cholesterol-lowering drug, of course, but the conclusion that for this group of drugs at least « outcome curves that do not separate for up to 30 months do not preclude eventual benefit » is of interest given that the median follow-up in BETonMACE was 3 months less than that. May strengthen the case for a « bolt on » extension.